In an aim to optimize the performance of changing clinical trials, Almac Clinical Services launched a supply chain solution – Almac Adapt – to provide sponsors with an adaptive supply strategy.
San Diego, CA-based NanoComposix received its drug manufacturing license which it said will ensure clients are able to use one vendor throughout the product life cycle.
Marken has opened a new depot and increased its logistics warehouse capacity fourfold to accommodate client needs for clinical drug product, clinical drug substance, and medical device storage.
Dassault Systèmes is set to acquire Medidata in an all-cash transaction valued at $5.8bn – a deal which will combine the power of modeling and simulation with data science to “catalyze the next generation of patient-inclusive therapeutics,” says CEO.
Aptar Group acquires two pharmaceutical services companies, Nanopharm and Gateway Analytical, to boost its analytical, testing, and development capabilities.
ElevateBio’s BaseCamp facility will provide “bench-to-bedside” services to its portfolio and partner companies – as the demand for cell and gene therapy CMOs “far outweighs the capacity,” says CEO.
The private equity firm Ampersand Capital has acquired Vibalogics with plans to increase development and manufacturing capabilities for complex viral products.
Vetter’s German sites will be supplied with only CO2 neutral energy from renewable energy sources as the company continues to work towards greater sustainability.
SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.
Marken executive says there is no such thing as a perfect clinical trial supply chain but with strategic planning and innovations there are opportunities to better serve the research industry.
Wasdell Group has acquired specialist manufacturer and packager, Honeywood Limited in an aim to build its manufacturing and packaging capacity in the UK to support European supply chain.
